Market Research Logo

The World Market for Anti-infectives Series: Volumes I - III - Antifungals, Antibacterials and Antivirals

Once a public health problem pegged for easy elimination, infectious diseases continue to be the leading cause of death worldwide. Despite improved methods of treating and preventing infection, including potent antibiotics, comprehensive immunization, and modern sanitation, infection still accounts for much serious illness, even in highly industrialized countries. Use this new Kalorama Information 3-volume series to evaluate your organization's position in the highly active anti-infectives market.

Volume I Abstract
The World Market for Antifungal Medications
The market for pharmaceuticals targeted to treat human fungal infections is poised to experience strong growth over the next few years. This report from Kalorama Information provides details and insight into the current $4+ billion worldwide market for anti-fungal treatments and the near 10% annual growth that will move the market in the near term.

Among the issues spurring growth is an aging population that is increasing the demand for medicines, including anti-fungal drugs, that will improve their lives as they grow older. In addition, the market is currently under-treated and underserved by existing anti-fungals, mainly in the amphotericin and a variety of azoles. Developing new successful and potent anti-fungal medications remains challenging, and the hunt has been underway for new therapeutics that will be able to improve efficacy, avoid multiple drug interactions, and offer an improved safety profile. Many drugs on the verge of the commercial market purport to achieve of these objectives. Optimizing their mode of delivery will help optimize their activity and reduce costs for the developer.

This report offers an overview of the world anti-fungal market, including insight into the anti-fungal activities of the major players such as Pfizer, Johnson & Johnson, Merck, Novartis, and others. It also examines the efforts of smaller companies that are developing their own niches, and which may be the source for many more effective anti-fungal therapies. The report forecasts the world market for anti-fungal therapies through 2006 and offers details on specific segments of the market. In addition, the report examines patent and exclusivity expiration timing and issues for many key anti-fungal pharmaceuticals.

Volume II Abstract
The World Market for Antibacterial Medications
November 2002

Antibiotic development has never proceeded at this pace or with this much urgency. Demand for effective antibacterial compounds is growing rapidly and companies are trying to fill their pipelines with products that can meet the challenges of increasingly stubborn infectious agents. By far the largest of the anti-infective segments, antibacterials represent approximately 65% of the $20+ billion world market in infectious disease drugs. However, it’s also the most crowded of the segments with big pharma and small biotech companies alike speeding toward the market. The second volume of Kalorama’s ongoing market study on anti-infectives tackles this large and dynamic segment with a global report on the clinical, regulatory, business, and even political forces that are shaping the rapidly changing antibiotic market.

Volume III Abstract
The World Market for Antiviral Medications
This report analyzes the world markets for human antiviral medications, focusing on the current market for and the development of drugs that are used to directly combat and treat viruses viral infections. For the purposes of this report, antivirals are drugs used to directly treat viral infection after it occurs. The report does not discuss products for the prevention of viral infection—that is, adult or pediatric vaccinations—and does not discuss other diseases, such as cancer or heart disease, that may be caused by a virus.

Market analysis is provided for various geographic regions and for various viral groups to 2006. The report profiles several companies involved in marketing or developing antiviral products, including Boehrinnger Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, and Merck, among others. The report generally reviews the nature and direction of research, as well as the markets for currently available drugs.

Market forecasts are based on an examination of current market conditions and on investigations into the development of new products by key companies. This information also is weighted with projected timing and the probability of receiving FDA approval to market products. The information presented in this report is the result of data gathered from interviews with company executives and other industry stakeholders. Company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press, provide supporting information. BR>
Volumes in this series may also be purchased separately. Individual chapters of each volume are also available via our Buy by the Slice feature.

Volume I: The World Market for Antifungal Medications
Volume II: The World Market for Antibacterial Medications
Volume III: The World Market for Antiviral Medications


Volume I: Antifungals

Executive Summary

    Perspective on Anti-Infective Pharmaceuticals

    Scope and Methodology

    Market Orientation

    • Market Segments
    • Market Segments
    • Major Market Drugs
    • Major Market Players
    • Major Pipeline Therapies
    • Market Expectations

    Issues Driving the Market Place

    Pharmaceutical Challenge

    • Drug Discovery
    • Slow-Evolving Therapies

Introduction

    Common Fungal Infection and Disease
    • Aspergillosis
    • Blastomycosis
    • Candidiasis
    • Cryptococcosis
    • Histoplasmosis
    • Diseases with Fungal Implications—AIDS

    Types of Infection

    Types of Therapies

    Infection Trends

    • HIV and AIDS
    • Sepsis
    • Children
    • Oropharyngeal Candidiasis
    • Onychomycosis
    • Mycoses

    Epidemiologic Summary

    Issues Facing Developers

    • Immunocompromised and Immunosuppressed Patients
    • Overprescribing and Drug Resistance

Emerging Therapies

    The Need for Antifungal Drugs

    Drug Patent and Exclusivity Expirations

    Antifungal Therapies under Development

    • Research Activity
    • Amphotericin B
    • Extending Current Therapies
    • Optimizing Pharmaceutical Delivery

The Market For Antifungal Pharmaceuticals

    World Market Overview

    A Growth Industry

    Market Issues

    • Generic Competition
    • OTC Switches

    Competitive Analysis

    Markets by Geographic Region

    Markets for Dermatologic Indications

    • U.S. Market
    • European Market
    • Japanese Market
    • Rest of World Market

    Markets for Nondermatologic Indications

    Miscellaneous Market Notes

    • Onychomycosis
    • Related Drug Delivery Market

Corporate Profiles

  • AM-Pharma BV
  • Aronex Pharmaceuticals Inc.
  • Aventis Pharma AG
  • Bentley Pharmaceuticals Inc.
  • Bristol-Myers Squibb Co.
  • Ecopia BioSciences Inc.
  • Elan Corp. plc
  • Fujisawa Healthcare Inc.
  • Genome Therapeutics Corp.
  • Gilead Sciences Inc.
  • GPC Biotec AG
  • Immtech International Inc.
  • Intrabiotics Pharmaceuticals Inc.
  • Isis Innovation Ltd.
  • Johnson and Johnson
  • Merck and Co. Inc.
  • Mylan Laboratories Inc.
  • Novartis International AG
  • Oxford GlycoSciences Ltd.
  • Pfizer Inc.
  • Prolifix Ltd.
  • Sankyo Co. Ltd.
  • Versicor Inc.

List of Exhibits

  • Table 2-1: Fungal Infections: Sources and Traditional Treatments
  • Table 2-2: Factors Contributing to Increased Prevalence of Fungal Infections
  • Table 2-3: Annual Incidence of Selected Fungal Infections in the United States, 2001
  • Table 3-1: Exclusivity Expirations for Key Antifungal Pharmaceuticals
  • Table 3-2: Patent Expirations for Key Antifungal Pharmaceuticals
  • Table 3-3: Selected Antifungal Therapies in the Pipeline
  • Table 3-4: Benefits of Alternative Drug Delivery Technologies
  • Table 4-1: The World Market for Anti-Infective Medications
  • Table 4-2: The World Market for Antifungal Medications
  • Table 4-3: Antifungal Prescription Drugs Now OTC Products
  • Table 4-4: Future Antifungal Prescription Drug Switches to OTC Status
  • Table 4-5: World Market for Antifungal Medications, Sales of Top Selling Products, 2001
  • Table 4-6: World Anti-infective Drug Market, Percentage Shares of the Top-Selling Antifungal Drugs, 2001
  • Table 4-7: World Market for Antifungal Medications, Sales of Top Selling Products, 2006
  • Table 4-8: The U.S. Market for Antifungal Medications, 2002-2006
  • Table 4-9: The European Market for Antifungal Medications, 2002-2006
  • Table 4-10: The South American Market for Antifungal Medications, 2002-2006
  • Table 4-11: The Japanese-Asian Market for Antifungal Medications, 2002-2006
  • Table 4-12: The African Market for Antifungal Medications, 2002-2006
  • Table 4-13: The Global Market Prescription Antifungal Dermatologic Drugs by Type, 2002-2006
  • Table 4-14: The U.S. Market for Prescription Antifungal Dermatologic Drugs, 2002-2006
  • Table 4-15: European Market for Prescription Antifungal Dermatologic Drugs, 2002-2006
  • Table 4-16: Japanese Market for Prescription Antifungal Dermatologic Drugs, 2002-2006
  • Table 4-17: Rest of World Prescription Antifungal Dermatologic Drugs, 2002-2006
  • Table 4-18: The World Market for Nondermatolgic Antifungal Medications, 2002-2006
  • Table 4-19: The U.S. Market for Nondermatolgic Antifungal Medications, 2002-2006
  • Table 4-20: The European Market for Nondermatolgic Antifungal Medications, 2002-2006
  • Table 4-21: The Japanese-Asian Market for Nondermatologic Antifungal Medications, 2002-2006
  • Table 4-22: The South American-African-ROW Market for Nondermatologic Antifungal Medications, 2002-2006

List of Figures

  • Figure 1-1: World Anti-Infective Drug Market by Type and Distribution Channel
  • Figure 2-1: Efficacy of CPE-125-Enhanced Clotrimazole Compared with Clotrimazole Alone
  • Figure 4-1: World Antifungal Drug Market by Type of Drug, 2002 and 2006
  • Figure 4-2: Incidence of Selected Oral Fungal Infections, 2000 and 2012
  • Figure 4-3: World Antifungal Drug Market, Market Shares of Top Competitors, 2001

Volume II: Anitbacterial Medications

Chapter One: Executive Summary

    Perspective on Anti Infective Pharmaceuticals

    Antibiotic Medications Overview

    • Current Drugs
    • The Need for New Drugs

    Market Orientation in Brief

    • Top Classes of Antibiotics
    • Top Classes of Antibiotics
    • Major Market Drugs
    • Major Market Players
    • Pipeline Therapies

    Issues Driving the Market

    • Antibiotic Resistance
    • Unnecessary Prescriptions
    • Patents

    Forecast Summary

    Scope and Methodology

Chapter Two: Introduction

    Microbiology of Infection
    • Gram Negative Bacteria
    • Gram Positive Bacteria

    Types of Compounds

    • Beta-lactamase
    • Clauvanic Acid
    • Imipenem
    • Sulbactam
    • Tazobactam
    • Cephalosporins
    • Macrolides
    • Sulfanilamide
    • Penicillin
    • Aminoglycosides
    • Chloramphenicol
    • Tetracyclines
    • Chlortetracycline
    • Quinolones
    • Fluoroquinolones

    Drug Use Patterns

    Resistance Issues

    • Trends
    • Macrolide Resistance
    • Streptococcus pneumoniae
    • Global Resistance Initiative
    • Natural Products

Chapter Three: Emerging Therapies

    Research Activities
    • Nasal Antibiotic
    • Iron Absorbing Mechanisms
    • Bacteriophages
    • Peptide Antibiotics
    • Targeting Enzymes
    • Blocking Pathways

    In the Pipeline

    Drug and Patent Exclusivity

Chapter Four: The World Market For Antibiotics

    Overview

    Markets by Geographic Region

    • United States
    • Europe
    • Japan-Asia, Latin America, Africa

    Market Share by Type of Drug

    Major Market Drugs and Players

    Generic Competition

    • Generic Antibiotics Market
    • Generic Product Trends

    Pediatric Antibiotic Market

    • Otitis Media
    • Acute Epiglottitis
    • Meningitis
    • Urinary Tract Infections
    • Pediatric Market Forecast

    Market Issues

    • Emerging Disease Market Opportunity
    • Bioterrorism

Chapter Five: Company Profiles

  • Abbott Laboratories
  • ActivBiotics
  • Agis Industries Ltd.
  • AntexPharma Inc.
  • Aventis Pharma AG
  • AstraZeneca PLC
  • Bayer AG
  • Biochemie GmbH
  • Bristol-Myers Squibb Co.
  • British Biotech plc
  • CollaGenex Pharmaceuticals Inc.
  • Corus Pharma Inc.
  • Cubist Pharmaceuticals Inc.
  • Daiichi Pharmaceutical Co. Ltd.
  • DepoMed Inc.
  • Ecopia BioSciences Inc.
  • Eli Lilly and Co.
  • Elite Pharma Pvt. Ltd.
  • Elitra Pharmaceuticals
  • Enanta Pharmaceuticals Inc.
  • Essential Therapeutics Inc.
  • First Horizon Pharmaceutical Corp.
  • Fujisawa Pharmaceutical Co. Ltd.
  • Genome Therapeutics Corp.
  • GlaxoSmithKline plc
  • Hoffmann La Roche Ltd.
  • Ibis Therapeutics
  • Intrabiotics Pharmaceuticals Inc.
  • Johnson and Johnson
  • Medicis Pharmaceutical Corp.
  • Merck and Co. Inc.
  • NAEJA Pharmaceutical Inc.
  • Norcarex Bio Corp.
  • PanTherix Ltd.
  • Paratek Pharmaceuticals Inc.
  • Pfizer Inc.
  • Recordati SpA
  • Salix Pharmaceuticals
  • Surya Pharmaceutical Ltd.
  • Taisho Pharmaceutical Co. Ltd.
  • Tanabe Seiyaku Ltd.
  • Toyama Chemical Co., Ltd.
  • Versicor Inc.

List of Exhibits

Chapter One

  • Figure 1-1: World Anti-Infective Drug Market Share by Type and Distribution Channel
  • Figure 1-2: Market Share for the Top Three Classes of Antibiotics
  • Table 1-1: Revenues of Top-Selling Prescription Antibiotic Drugs
  • Table 1-2: World Prescription Antibiotic Drug Market, Percentage Shares of Top Competitors

Chapter Two

  • Figure 2-1: Prescription Drug Use in the United States
  • Table 2-1: US Incidence Data for Selected Bacterial Disease
  • Table 2-2: Selected Resistent Infection Statistics
  • Table 2-3: Mortality Statistics for Major Infectious Diseases
  • Table 2-4: Epidemiologic Statistics for Most Common Infections

Chapter Three

  • Table 3-1: Notable Antibiotic Therapies in the Development Pipeline
  • Table 3-2: Exclusivity Expirations for Key Antibiotic Pharmaceuticals
  • Table 3-3: Patent Expirations for Key Antibiotic Pharmaceuticals

Chapter Four

  • Table 4-1: The World Market for Anti-Infective Medications, 2002-2006
  • Table 4-2: The World Market for Antibiotic Medications, 2002-2006
  • Table 4-3: The U.S. Market for Antibiotic Medications, 2002-2006
  • Table 4-4: The European Market for Antibiotic Medications, 2002-2006
  • Table 4-5: The Japanese-Asian Market for Antibiotic Medications, 2002-2006
  • Table 4-6: The Latin American Market for Antibiotic Medications, 2002-2006
  • Table 4-7: The African Market for Antibiotic Medications, 2002-2006
  • Figure 4-1: World Antibiotic Drug Market, Share by Type of Drug
  • Table 4-8: Revenues of Top-Selling Prescription Antibiotic Drugs
  • Figure 4-2: Market Share of Top-Selling Prescription Antibiotic Drugs
  • Table 4-9: Prescription Generic Anti-infective Drug ANDA Approvals, 2001
  • Table 4-10: The World Market for Antibiotic Medications Generic vs Branded Revenues, 2002-2006
  • Figure 4-3: Market Share of Generic vs Branded Antibiotic Medications 2002 and 2006
  • Table 4-11: Selected Prescription Antibiotics for Pediatric Administration
  • Table 4-12: The World Market for Antibiotic Medications Pediatric vs Non-Pediatric Revenues, 2002-2006
  • Table 4-13: Re-Emerging Infectious Disease, Selected Recent Cases

Volume III: Anti-viral Medications

Chapter One: Executive Summary

    Infection and Viruses

    Types of Antiviral Drugs

    • Nucleoside Therapies
    • Non-nucleoside Reverse Transcriptase Inhibitors
    • Protease Inhibitors

    Market Orientation

    • Major Market Drugs
    • Major Market Players

    Market Expectations

    • Key Pipeline Therapies
    • Issues Driving the Market Place
    • Forecast

    Scope and Methodology

Chapter Two: Introduction

    Types of Viruses
    • HIV/AIDS
    • The Hepatitises
    • Herpes Simplex
    • Epstein-Barr Virus (Mononucleosis)
    • Influenza
    • Other Significant Viruses

    Antiviral Drugs

    • Nuceloside Therapies
    • Protease Inhibitors
    • Heat Shock Proteins
    • Miscellaneous Viral Therapies

    Disease Incidence and Statistics

    • HIV and AIDS
    • Hepatitis
    • Herpes
    • Human Papilloma Virus
    • Influenza

    Ongoing Clinical Trials

Chapter Three: Emerging Disease And Research

    HIV Cases on the Rise

    Research Trends

    • The Need for New Therapies
    • Antisense Oligonucleotides
    • Immunomodulators
    • Combination Treatment
    • DNA Bactofection
    • RNA Interference
    • GB Virus
    • Bioterror Research

    In the Pipeline

    Drug and Patent Exclusivity

    Patent and Exclusivity Differences

    Therapies to Lose Protection

Chapter Four: The Market For Antiviral Pharmaceuticals

    World Market Overview

    Market Share by Type of Drug

    Major Market Drugs and Players

    Markets by Disease

    • HIV/AIDS
    • Hepatitis
    • Herpes
    • Influenza
    • Miscellaneous Viral Therapeutics

    Geographical Markets

    Generic Competition

Chapter Five: Corporate Profiles

  • Abbott Laboratories
  • Advanced Viral Research Corp.
  • Biota Holdings Ltd.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co.
  • Genelabs Technologies, Inc.
  • GlaxoSmithKline plc
  • Gilead Sciences Inc.
  • Hemispherx Biopharma Inc.
  • F. Hoffmann-La Roche Ltd.
  • Hybridon Inc.
  • ICN Pharmaceuticals Inc.
  • ICN Pharmaceuticals Inc.
  • Immtech International Inc.
  • Isis Pharmaceuticals Inc.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Pharmasset Inc.
  • Progenics Pharmaceuticals Inc.
  • Ribozyme Pharmaceuticals Inc.
  • Schering-Plough Corp.
  • SciClone Pharmaceuticals Inc.
  • Stressgen Biotechnologies Corp.
  • Trimeris Inc.
  • Viral Genetics Inc.
  • ViroPharma Inc.

Executive Summary

  • Figure 1-1: World Anti-Infective Drug Market by Type and Distribution Channel
  • Table 1-1: Top-Selling Prescription Antiviral Drugs 2002
  • Table 1-2: World Prescription Antiviral Drug Market, Market Shares of Top Competitors

Introduction

  • Table 2-1: HIV Statistics
  • Table 2-2: Prevalence of Chronic Hepatitis Infections in the United States by Type 2000
  • Table 2-3: Number of Ongoing Clinical Trials for Virus-Related Disease

Emerging Disease And Research

  • Table 3-1: Selected Late Stage Developmental Antiviral Therapies
  • Table 3-2: Exclusivity Expirations for Key Antiviral Drugs
  • Table 3-3: Patent Expirations for Key Antiviral Drugs

World Market For Antiviral Pharmaceuticals

  • Table 4-1: The World Market for Anti-Infective Medications
  • Table 4-2: The World Market for Antiviral Medications
  • Figure 4-1: World Antiviral Drug Market
  • Figure 4-2: World Antiviral Drug Market Share by Disease Type
  • Figure 4-3: World Antiviral Drug Market by Type of Drug 2002 & 2006
  • Table 4-3: World Market for Antiviral Drugs Revenues by Top-Selling Product
  • Figure 4-4: World Market for Antiviral Drugs Market Share by Top-Selling Product
  • Figure 4-5: World Market for Antiviral Drugs Market Share by Top Competitor
  • Figure 4-6: Top Ten Most Recognized Antiviral Brands
  • Table 4-4: Global summary of the HIV/AIDS epidemic December 2002
  • Table 4-5: Regional HIV/AIDS Statistics and Features End of 2002
  • Table 4-6: World Antiviral Drug Market HIV Drugs 2002-2006
  • Table 4-7: World Antiviral Drug Market Hepatitis Drugs 2002-2006
  • Table 4-8: World Antiviral Drug Market Herpes Drugs 2002-2006
  • Table 4-9: World Antiviral Drug Market Influenza Drugs 2002-2006
  • Table 4-10: World Antiviral Drug Market Miscellaneous Therapeutics 2002-2006
  • Table 4-11: World Antiviral Drug Market by Geographical Segment (U.S., Europe, Japan, Rest of World) 2002-2006
  • Figure 4-7: World Antiviral Drug Market Market Share by Geographical Segment (U.S., Europe, Japan, Rest of World) 2002
  • Table 4-12: World Antiviral Drug Market Generic Versus Branded Revenues

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report